However, targeting HER2 was not considered a standard treatment for DCIS yet despite the high expression rate, because we have not yet elucidated the impact of HER2 expression on DCIS cell invasion and long-term prognosis of patients (Siziopikou et al., 2013; Cobleigh et al., 2021; Van Bockstal, Libbrecht & Galant, 2021). Here, ERBB2 is linked to ductal breast carcinoma in situ.